Uptravi 800 mcg Film-Coated Tablets containing the active ingredient Selexipag represent a groundbreaking advancement in the treatment of pulmonary arterial hypertension (PAH). Manufactured by Janssen Pharmaceuticals, Uptravi is a selective prostacyclin receptor agonist that plays a critical role in reducing pulmonary artery pressure and improving exercise capacity in patients with PAH. It is a key therapy for those requiring long-term management of this rare but life-threatening condition.
Selexipag, the active substance in Uptravi, works by mimicking the action of prostacyclin, a natural compound in the body that helps dilate blood vessels and inhibit abnormal growth of smooth muscle cells within the pulmonary arteries. This dual mechanism not only reduces blood vessel constriction but also prevents vessel remodeling, addressing the underlying causes of PAH progression.
Key Benefits of Uptravi 800 mcg:
- Slows Disease Progression: Clinically proven to delay the worsening of PAH and reduce hospitalization rates.
- Improves Exercise Capacity: Enhances patients’ ability to engage in physical activities, improving their quality of life.
- Oral Prostacyclin Pathway Therapy: Convenient oral formulation compared to traditional intravenous prostacyclin therapies.
- Combination Treatment: Often used alongside endothelin receptor antagonists (ERAs) and phosphodiesterase-5 inhibitors (PDE-5i) for comprehensive PAH management.
Dosage & Administration:
- Dosage: Individualized based on patient tolerance, typically starting from a lower dose and gradually increased to the therapeutic level.
- Administration: Oral use, preferably taken with food to minimize gastrointestinal side effects.
- Standard Dose: 800 mcg twice daily or as prescribed by a healthcare provider.
Possible Side Effects:
- Headache, jaw pain, nausea, diarrhea, muscle pain, flushing.
- Dose adjustments or symptomatic treatment may be necessary if side effects persist.
Warnings & Precautions:
- Not suitable for patients with severe liver impairment.
- Avoid use during pregnancy unless absolutely necessary.
- Regular monitoring of liver function and cardiovascular health is advised.
Why Choose Uptravi 800 mcg?
Uptravi stands out as a leading oral treatment for PAH because it targets the prostacyclin pathway, a vital but often underutilized approach in PAH therapy. Its oral formulation offers greater convenience and patient adherence compared to intravenous prostacyclin analogs, transforming the way PAH patients manage their condition.
Patients choosing Uptravi 800 mcg Selexipag tablets can expect a therapy designed to improve their long-term health outcomes, enabling a more active and fulfilling life while living with pulmonary arterial hypertension.
Storage Instructions:
- Store at room temperature (below 30°C).
- Keep away from moisture and heat.
- Keep out of reach of children.
Trusted Source & Manufacturer:
- Brand: Uptravi
- Manufacturer: Janssen Pharmaceuticals
- Country of Origin: Europe
Buy Uptravi 800 mcg Online:
We offer original Uptravi 800 mcg film-coated tablets sourced directly from Janssen Pharmaceuticals. Contact us for competitive pricing and fast worldwide delivery. Secure your supply of Selexipag Uptravi 800 mcg to ensure uninterrupted PAH treatment.
Değerlendirmeler
Henüz değerlendirme yapılmadı.